Fenwick & West represented Dermira, Inc. (Nasdaq: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, in its initial public offering. The company sold 7,812,500 shares of common stock at a price to the public of $16.00 per share. Concurrently with the offering, Dermira also sold through a private placement 468,750 shares of its common stock to UCB S.A., an existing stockholder, at the initial public offering price.
Citigroup and Leerink Partners acted as joint book-running managers for the offering. Guggenheim Securities and Needham & Company acted as co-managers.
The Fenwick transaction team included corporate attorneys Douglas Cogen, Michael Brown, Robert Freedman, Morgan Casey and Liza Kostinskaya; executive compensation and employee benefits attorneys Gerald Audant and Grace Chen; and intellectual property attorneys Lisa Kenkel and Michael Shuster.